KORU Medical Systems, Inc. (KRMD) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, KORU Medical Systems, Inc.'s filing signal turned positive.

KORU Medical Systems develops, manufactures, and commercializes patient-centric, large-volume subcutaneous infusion solutions, primarily for the subcutaneous drug delivery market. Its core products, the FREEDOM Infusion Systems, include syringe drivers, safety needle sets, and precision flow rate tubing, used for delivering therapies like immunoglobulin for Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company derives revenue from domestic and international sales of these products, as well as from pharma services and clinical trials, which include engineering services to customize its systems for biopharmaceutical companies. KORU Medical aims to expand its leadership in the subcutaneous immunoglobulin (SCIg) market and extend its expertise into emerging subcutaneous drug therapies, leveraging its FREEDOM System and future innovations.

Revenue is generated from the sale of KORU Medical's FREEDOM Infusion Systems (syringe drivers, tubing, and needles) for subcutaneous drug delivery, primarily immunoglobulin therapies. Additional revenue comes from pharma services and clinical trials, including engineering services for drug development and customization of infusion systems.